System and method for generating pain inhibition pulses using an implantable cardiac stimulation device

• US 7,158,826 B1
• Filed: 04/30/2003
• Issued: 01/02/2007
• Est. Priority Date: 04/30/2003
• Status: Active Grant

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Inventors: Kroll, Mark W., Fain, Eric
• Primary Examiner(s): Evanisko; George R.
• Assistant Examiner(s): KAHELIN, MICHAEL WILLIAM
• Application Number:
  US10/428,217
• Time in Patent Office: 1,343 Days
• Field of Search: 607/4, 607/5, 607/7, 607/9, 607/46, 607/63, 607/48
• US Class Current: 607/5
• CPC Class Codes: A61N 1/36071 Pain
• CPC Class Codes: A61N 1/3906 characterised by the form of the shockwave
• CPC Class Codes: A61N 1/3925 Monitoring; Protecting
• CPC Class Codes: A61N 1/3956 Implantable devices for applying electric shocks to the heart, e.g. for cardioversion

Abstract

Improved pre-pulse pain inhibition (PPI) techniques are provided for reducing pain caused by cardioversion shocks, including a technique for determining preferred pulse durations for high voltage PPI pulses. Techniques for generating both low voltage and high voltage PPI pulses are also set forth. In one example, a train of low voltage pre-pulses is delivered to the heart, followed by a single high voltage “sliver” pulse, followed by a main high voltage cardioversion shock. The train of low voltage pre-pulses is delivered while alternating between atrial and ventricular tip electrodes, with the device housing used as a return electrode. The sliver pulse, which may be only 20 or 30 microseconds in duration, is instead delivered between electrodes implanted in the heart, such as between the RV coil and SVC coil. The main shock is delivered between the RV coil and the device housing.

Claims

1. A method for reducing pain associated with an electrical cardiac shock delivered to a patient by a shocking circuit of an implantable cardiac stimulation device, the method comprising:

detecting an arrhythmia requiring a cardioversion shock;

generating an electrical pre-pulse pain inhibition (PPI) sliver pulse for delivery to the patient, the sliver pulse having a voltage set to a cardioversion shock voltage level and having a duration no greater than 50 microseconds;

delivering the PPI sliver pulse to the patient via at least one electrode located in or on the patient'"'"'s heart;

generating a main electrical cardioversion shock for delivery to the patient to terminate the arrhythmia, the main shock having an initial voltage also set to the cardioversion shock voltage level; and

delivering the main electrical cardioversion shock to the patient.

2. The method of claim 1 wherein the voltage for both the cardioversion shock and the sliver pulse is at least 100 volts.

3. The method of claim 1 wherein the main shock has a duration of 1–

3 milliseconds.

4. The method of claim 1 further comprising:

inputting a rheobase voltage and a chronaxie time associated with nerve tissue; and

determining a pulse duration for the sliver pulse based upon the rheobase voltage, the chronaxie time, and the voltage of the sliver pulse.

5. The method of claim 4 wherein determining the pulse duration comprises:

calculating an minimum theoretical pulse duration (d_T) using

$d_T=\frac{V_R<br><br>d_c}{V-V_R}$

wherein V is the selected pulse voltage, V_R is the rheobase voltage, and d_C is the chronaxie time.

6. The method of claim 5 wherein the shocking circuit comprises a minimum bridge circuit time and wherein determining the pulse duration comprises setting the pulse duration equal to the greater of the minimum pulse duration (d_T) and the minimum bridge circuit time.

7. The method of claim 1 wherein the sliver pulse is a monophasic pulse.

8. The method of claim 1 wherein the sliver pulse is a biphasic pulse.

9. The method of claim 1 wherein the sliver pulse is delivered between a first set of electrodes and the main shock is delivered between a second set of electrodes, more widely spaced than the first.

10. The method of claim 9 wherein the sliver pulse is delivered between an RV coil and an SVC coil and wherein the main shock is delivered between the RV coil and a housing of the implantable device.

11. The method of claim 1 further comprising generating a train of non-sliver PPI pulses prior to the sliver pulse, with the train of pulses each having a voltage substantially less that that of the sliver pulse.

12. The method of claim 11 wherein each of the train of pulses has a voltage between 7.5 and 10 volts whereas the sliver pulse and the main shock have voltages of at least 100 volts.

13. The method of claim 11 wherein the train of pulses includes ten to twenty individual pulses.

14. The method of claim 11 wherein each pulse in the train of pulses has a duration of between 0.25 to 0.50 milliseconds and wherein the pulses are separated by between 2.0 and 3.0 milliseconds.

15. The method of claim 11 wherein delivery of a first pulse of the train of pulses is timed so as to depolarize the ventricles and wherein the last of the train of pulses is delivered prior to a resulting ventricular repolarization.

16. The method of claim 11 wherein the train of pulses is selectively delivered using either an atrial tip electrode or a ventricular tip electrode, with a housing of the device used as a return electrode.

17. The method of claim 16 wherein the train of pulses are delivered by alternating between the atrial tip electrode and the ventricular tip electrode.

18. A system for reducing pain associated with an electrical cardiac shock delivered to a patient by an implantable cardiac stimulation device, the system comprising:

means for generating a pre-pulse pain inhibition (PPI) sliver pulse for delivery to the patient'"'"'s heart, the sliver pulse having a voltage set to a cardioversion shock voltage level and having a duration no greater than 50 microseconds; and

means for generating a cardioversion shock for delivery to the patient, the main shock having an initial voltage also set to the cardioversion shock voltage level.